List view / Grid view
17 May 2016 | By The Black Swan Analysis
The Black Swan Analysis team are delighted to announce that their Senior Analyst, Christopher Bell, has been awarded the highly respected ‘Ian Burgess Award’ at the Annual British Healthcare Intelligence Association (BHBIA) conference in London...
13 May 2016 | By Victoria White, Digital Content Producer
Pfizer has announced results of two Phase III studies demonstrating the immunogenicity of Trumenba against invasive meningococcal B strains...
13 May 2016 | By Victoria White, Digital Content Producer
The European Commission has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation...
13 May 2016 | By Victoria White, Digital Content Producer
FRESCO is a Phase III pivotal trial of fruquintinib (HMPL-013) in third-line locally advanced or metastatic colorectal cancer (CRC)...
13 May 2016 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce the appointment of James Bichener as Finance Director. James brings a wealth of financial expertise gained both within executive search and beyond to augment the strategic strengths of the senior management team. “We are extremely fortunate to attract such…
13 May 2016 | By Victoria White, Digital Content Producer
Reviewing data from the study, the DMC observed that patients receiving riociguat were at a possible increased risk for death and other serious adverse events...
12 May 2016 | By Victoria White, Digital Content Producer
Prenoxad Injection has been approved in Sweden, Denmark, Ireland, Finland and Estonia following the successful completion of a DCP...
12 May 2016 | By Victoria White, Digital Content Producer
The FDA has granted Orphan Drug Designation for selumetinib for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer (DTC)...
12 May 2016 | By Victoria White, Digital Content Producer
Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue...
12 May 2016 | By Victoria White, Digital Content Producer
Empliciti (elotuzumab) is approved for use with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy...
12 May 2016 | By Victoria White, Digital Content Producer
In draft guidance, NICE has said ‘no’ to Opdivo for the treatment of patients with non-squamous NSCLC whose disease has progressed after prior chemotherapy...
11 May 2016 | By Victoria White, Digital Content Producer
The approval of Opdivo + Yervoy represents the first and only approved combination of two Immuno-Oncology agents in the European Union (EU)...
11 May 2016 | By Victoria White, Digital Content Producer
University of Manchester and CMFT researchers are to work with Orchard Therapeutics to test a stem cell gene therapy for Sanfilippo disease in a human trial...
11 May 2016 | By Victoria White, Digital Content Producer
Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.
11 May 2016 | By Victoria White, Digital Content Producer
A subsidiary of Jazz Pharmaceuticals has acquired 100% of the shares of Alizé Pharma II in a deal valued at up to €18 million...
